© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 22, 1698-1703,
November 21, 2001
© 2001 Oxford University Press
ACCELERATED DISCOVERY |
Loss of Imprinting of Insulin-Like Growth Factor-II (IGF2) Gene in Distinguishing Specific Biologic Subtypes of Wilms Tumor
Affiliations of authors: J. D. Ravenel, E. L. Niemitz, T. M. Jayawardena, H. Uejima, A. P. Feinberg (Institute of Genetic Medicine), E. J. Perlman (Department of Pathology), The Johns Hopkins University School of Medicine, Baltimore, MD; K. W. Broman, Department of Biostatistics, Bloomberg School of Public Health, The Johns Hopkins University; D. W. Bell, D. A. Haber, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown.
Correspondence to: Andrew P. Feinberg, M.D., M.P.H., Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Ross 1064, 720 Rutland Ave., Baltimore, MD 21205 (e-mail: afeinberg{at}jhu.edu).
Background: Loss of imprinting (LOI) of the insulin-like growth factor-II (IGF2) gene, an epigenetic alteration associated with expression of the normally silent maternal allele, was observed first in Wilms tumor. Although LOI has subsequently been detected in most adult tumors, the biologic role of LOI in cancer remains obscure. We analyzed the imprinting status of Wilms tumors with respect to pathologic subtype, stage, and patient's age at diagnosis and examined the expression of genes potentially affected by LOI. Methods: Of 60 Wilms tumors examined, 25 were informative for an ApaI polymorphism in the IGF2 gene, allowing analysis of allele-specific gene expression, and could be classified by pathologic subtype. Gene expression was measured quantitatively by real-time polymerase chain reaction, and pathologic analysis was blinded for genetic status. All statistical tests were two-sided. Results: We observed LOI of IGF2 in nine (90%) of 10 Wilms tumors classified as having a pathologic subtype associated with a later stage of renal development and in only one (6.7%) of 15 Wilms tumors with a pathologic subtype associated with an earlier stage of renal development (P<.001). LOI was associated with a 2.2-fold increase (95% confidence interval [CI] = 1.6-fold to 3.1-fold) in IGF2 expression (P<.001). Children whose Wilms tumors displayed LOI of IGF2 were statistically significantly older at diagnosis (median = 65 months; interquartile range [IQR] = 47–83 months) than children whose tumors displayed normal imprinting (median = 24 months; IQR = 13–35 months; P<.001). Conclusions: These data demonstrate a clear relationship between LOI and altered expression of IGF2 in Wilms tumors and provide a molecular basis for understanding the divergent pathogenesis of this cancer. Analysis of LOI could provide a valuable molecular tool for the classification of Wilms tumor.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. P. Feinberg Epigenetics at the Epicenter of Modern Medicine JAMA, March 19, 2008; 299(11): 1345 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. T. Bjornsson, L. J. Brown, M. D. Fallin, M. A. Rongione, M. Bibikova, E. Wickham, J.-B. Fan, and A. P. Feinberg Epigenetic Specificity of Loss of Imprinting of the IGF2 Gene in Wilms Tumors J Natl Cancer Inst, August 15, 2007; 99(16): 1270 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Prince, E. J. Foulstone, O. J. Zaccheo, C. Williams, and A. B. Hassan Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor Mol. Cancer Ther., February 1, 2007; 6(2): 607 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Murphy, Z. Huang, Y. Wen, M. A. Spillman, R. S. Whitaker, L. R. Simel, T. D. Nichols, J. R. Marks, and A. Berchuck Frequent IGF2/H19 Domain Epigenetic Alterations and Elevated IGF2 Expression in Epithelial Ovarian Cancer Mol. Cancer Res., April 1, 2006; 4(4): 283 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kaneda and A. P. Feinberg Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk Cancer Res., December 15, 2005; 65(24): 11236 - 11240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Yuan, C.-M. Li, D. J. Yamashiro, J. Kandel, H. Thaker, V. V. Murty, and B. Tycko Genomic Profiling Maps Loss of Heterozygosity and Defines the Timing and Stage Dependence of Epigenetic and Genetic Events in Wilms' Tumors Mol. Cancer Res., September 1, 2005; 3(9): 493 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sakatani, A. Kaneda, C. A. Iacobuzio-Donahue, M. G. Carter, S. de Boom Witzel, H. Okano, M. S. H. Ko, R. Ohlsson, D. L. Longo, and A. P. Feinberg Loss of Imprinting of Igf2 Alters Intestinal Maturation and Tumorigenesis in Mice Science, March 25, 2005; 307(5717): 1976 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Woodson, A. Flood, L. Green, J. A. Tangrea, J. Hanson, B. Cash, A. Schatzkin, and P. Schoenfeld Loss of Insulin-Like Growth Factor-II Imprinting and the Presence of Screen-Detected Colorectal Adenomas in Women J Natl Cancer Inst, March 3, 2004; 96(5): 407 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Breslow, R. Norris, P. A. Norkool, T. Kang, J. B. Beckwith, E. J. Perlman, M. L. Ritchey, D. M. Green, and K. E. Nichols Characteristics and Outcomes of Children With the Wilms Tumor-Aniridia Syndrome: A Report From the National Wilms Tumor Study Group J. Clin. Oncol., December 15, 2003; 21(24): 4579 - 4585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Diaz-Meyer, C D Day, K Khatod, E R Maher, W Cooper, W Reik, C Junien, G Graham, E Algar, V M Der Kaloustian, et al. Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome J. Med. Genet., November 1, 2003; 40(11): 797 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Schumacher, S. Schuhen, S. Sonner, A. Weirich, I. Leuschner, D. Harms, J. Licht, S. Roberts, and B. Royer-Pokora Two Molecular Subgroups of Wilms' Tumors with or without WT1 Mutations Clin. Cancer Res., June 1, 2003; 9(6): 2005 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Vu, N. V. Chuyen, T. Li, and A. R. Hoffman Loss of Imprinting of IGF2 Sense and Antisense Transcripts in Wilms' Tumor Cancer Res., April 15, 2003; 63(8): 1900 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Cui, M. Cruz-Correa, F. M. Giardiello, D. F. Hutcheon, D. R. Kafonek, S. Brandenburg, Y. Wu, X. He, N. R. Powe, and A. P. Feinberg Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk Science, March 14, 2003; 299(5613): 1753 - 1755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Morison, D. M.O. Becroft, and A. E. Reeve Re: Loss of Imprinting of Insulin-Like Growth Factor-II (IGF2) Gene in Distinguishing Specific Biologic Subtypes of Wilms Tumor J Natl Cancer Inst, December 4, 2002; 94(23): 1809 - 1809. [Full Text] [PDF]
|
|
|
|
|
|
H. Cui, P. Onyango, S. Brandenburg, Y. Wu, C.-L. Hsieh, and A. P. Feinberg Loss of Imprinting in Colorectal Cancer Linked to Hypomethylation of H19 and IGF2 Cancer Res., November 15, 2002; 62(22): 6442 - 6446. [Abstract] [Full Text] [PDF]
|
|